We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$22.8B
AUM Growth
-$4.8M
Cap. Flow
+$69.6M
Cap. Flow %
0.31%
Top 10 Hldgs %
39.53%
Holding
188
New
24
Increased
37
Reduced
34
Closed
37

Top Buys

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$580M
2
ADSK icon
Autodesk
ADSK
+$544M
3
MCK icon
McKesson
MCK
+$342M
4
TMO icon
Thermo Fisher Scientific
TMO
+$288M
5
IBIT icon
iShares Bitcoin Trust
IBIT
+$275M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$508M
2
CRM icon
Salesforce
CRM
+$266M
3
NOW icon
ServiceNow
NOW
+$264M
4
SPGI icon
S&P Global
SPGI
+$246M
5
SHW icon
Sherwin-Williams
SHW
+$212M

Sector Composition

Rank Sector Weight
1 Healthcare 33.98%
2 Technology 14.71%
3 Financials 12.17%
4 Communication Services 7.05%
5 Industrials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$209M
$14.6M 0.06%
2,570,700
+278,700
+12% +$1.8M
TYRA icon
77
Tyra Biosciences
TYRA
$1.55B
$13.9M 0.06%
+1,000,981
New +$18.2M
TNGX icon
78
Tango Therapeutics
TNGX
$4.03B
$12.4M 0.05%
+4,000,000
New +$18.6M
ENTA icon
79
Enanta Pharmaceuticals
ENTA
$392M
$12.1M 0.05%
2,108,262
– –
ARWR icon
80
Arrowhead Research
ARWR
$12.3B
$11.8M 0.05%
+628,800
New +$12.9M
NUVL
81
DELISTED
Nuvalent
NUVL
$11.7M 0.05%
150,000
– –
GEHC icon
82
GE HealthCare
GEHC
$33.8B
$9.69M 0.04%
+124,000
New +$10.5M
MARA icon
83
Marathon Digital Holdings
MARA
$4.35B
$9.31M 0.04%
+555,000
New +$11.2M
BBOT
84
BridgeBio Oncology
BBOT
$728M
$6.3M 0.03%
600,000
– –
BDSX icon
85
Biodesix
BDSX
$281M
$5.83M 0.03%
190,571
-41,269
-18% -$1.21M
DYN icon
86
Dyne Therapeutics
DYN
$4.87B
$5.4M 0.02%
229,121
-198,879
-46% -$5.88M
SLNO
87
DELISTED
Soleno Therapeutics
SLNO
$4.05M 0.02%
+90,000
New +$4.66M
GRND.WS
88
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$3.65M 0.02%
540,000
– –
MTAL
89
DELISTED
Metals Acquisition
MTAL
$3.51M 0.02%
330,901
-79,296
-19% -$979K
VNET
90
VNET Group
VNET
$1.91B
$3.08M 0.01%
650,000
– –
ALVO icon
91
Alvotech
ALVO
$1.5B
$2.64M 0.01%
199,675
– –
JANX icon
92
Janux Therapeutics
JANX
$1.06B
$2.57M 0.01%
+48,000
New +$2.54M
SMC
93
Summit Midstream
SMC
$470M
$2.2M 0.01%
58,214
– –
PRME icon
94
Prime Medicine
PRME
$615M
$2.19M 0.01%
750,000
– –
ELEV
95
DELISTED
Elevation Oncology
ELEV
$1.98M 0.01%
3,527,482
– –
GATE
96
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.65M 0.01%
150,000
– –
MDGL icon
97
Madrigal Pharmaceuticals
MDGL
$11.9B
$1.02M ﹤0.01%
3,319
– –
FBRX icon
98
Forte Biosciences
FBRX
$1.63B
$795K ﹤0.01%
35,000
-37,413
-52% -$445K
TVRD
99
Tvardi Therapeutics
TVRD
$24.8M
$794K ﹤0.01%
43,228
-1
-0% -$11
ROIV icon
100
Roivant Sciences
ROIV
$26.2B
$438K ﹤0.01%
37,000
– –
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2024 Portfolio in Review

As of Q4 2024, Thomas Steyer held 188 positions worth $22.8B, down 0.02% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer's Q4 2024 filing shows 24 new, 37 increased, 34 reduced and 37 closed positions. Its largest new stake was Autodesk: 1,841,800 shares worth $544M. The largest sale was CATALENT, INC., an estimated $508M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

  • Thomas Steyer's largest Q4 2024 buy was Autodesk: 1,841,800 shares worth $544M.
  • Thomas Steyer added most to Discover Financial Services in Q4 2024, an estimated $580M increase.
  • Thomas Steyer's biggest Q4 2024 reduction was Salesforce, cutting an estimated $266M.
  • Thomas Steyer fully exited CATALENT, INC. in Q4 2024, selling an estimated $508M.
  • Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q4 2024.
  • Thomas Steyer opened 24 new positions and closed 37 in Q4 2024.
  • Thomas Steyer's portfolio value fell 0.02% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.